Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.29 BRL | -10.55% | -6.91% | -42.17% |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company shows low valuation levels, with an enterprise value at 0.22 times its sales.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-42.17% | 254M | - | ||
-37.88% | 13.99B | B- | ||
-33.12% | 10.67B | B | ||
-22.64% | 6.75B | B | ||
+12.54% | 6.29B | C | ||
-11.17% | 5.88B | C+ | ||
+75.00% | 4.96B | C | ||
-2.92% | 4.54B | D- | ||
-9.20% | 3.74B | B | ||
-19.40% | 3.16B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- PGMN3 Stock
- Ratings Empreendimentos Pague Menos S.A.